Latvian LongeVC has invested in the US biotech startup Rubedo Life Sciences , which developed a drug discovery platform that helps to identify and target cells that cause aging. The €37,3M Series A round was led by Californian Khosla Ventures and London-based Ahren Innovation Capital, with participation from Saudi Arabian non-profit organization Hevolution Foundation, California-based VC R42 Group, Houston-based Modi Ventures, Singaporean Cerigo Investments, Californian investment firms Shanda Group and Refactor Capital, Italian Angels for Growth, and others.